Publications by authors named "N L Jebsen"
Background: Rare primary malignant bone sarcomas (RPMBS) account for 5%-10% of primary high-grade bone tumors and represent a major treatment challenge. The outcome of patients with RPMBS enrolled in the EUROpean Bone Over 40 Sarcoma Study (EURO-B.O.
View Article and Find Full Text PDFBackground/aim: Sarcoma patients' experiences of their health-related quality of life and late effects following particle therapy are sparse. Such knowledge is essential to optimize treatment compliance and follow-up care related to this rapidly developing, but still centralized treatment modality.
Patients And Methods: This qualitative study has an explorative design and applies a phenomenological and hermeneutical approach based on semi-structured interviews with 12 bone sarcoma patients who had undergone particle therapy abroad.
Article Synopsis
- Researchers created a new risk model called G-score to better predict if patients with solitary fibrous tumors will have recurrences, or if their disease will come back.
- They studied a large group of 318 patients worldwide and found that 33% had their disease come back over time.
- The G-score did a really good job at predicting who was at low risk for recurrence compared to other models, which means patients with a low score might not need to visit the doctor as often.
Purpose: LTX-315 is a first-in-class, 9-mer membranolytic peptide that has shown potent immunomodulatory properties in preclinical models. We conducted a phase I dose-escalating study of intratumoral LTX-315 administration in patients with advanced solid tumors.
Patients And Methods: Thirty-nine patients were enrolled, receiving LTX-315 injections into accessible tumors.
Background: We recently reported outcomes from a Scandinavian Sarcoma Group adjuvant study (SSG XX group A) conducted on localized and operable high risk soft tissue sarcoma (STS) of the extremities and trunk wall. SSG XX, group B, comprised of patients in a defined cohort with locally advanced STS considered at high risk for intralesional surgery. These patients received preoperative accelerated radiotherapy, together with neoadjuvant and adjuvant chemotherapy.
View Article and Find Full Text PDF